Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).
22-10-2018 | Non-small-cell lung cancer | ESMO 2018 | Video